GlassScriptPhysician profile
Susan Weiser Crow
NPI 1790975910
$1,236.52
in general payments reported to CMS, 2019-2025
25 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $177 · 2021: $314 · 2022: $144 · 2023: $121 · 2024: $112 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $180.27 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $117.43 | 2021-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Neos Therapeutics, LP | $114.96 | 2020-2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $111.78 | 2019-2025 | Onyda Xr |
| Corium, LLC | $103.37 | 2021-2025 | Azstarys |
| Adlon Therapeutics L.P. | $55.22 | 2020-2021 | |
| Pfizer INC. | $51.07 | 2019-2024 | |
| Sanofi Pasteur INC. | $48.57 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $42.26 | 2021-2023 | Koselugo |
| Ultragenyx Pharmaceutical INC. | $36.89 | 2020-2022 | |
| Kaleo, INC. | $36.33 | 2019-2020 | |
| Seqirus USA INC | $34.98 | 2024-2025 | Flucelvax |
| Genentech USA, INC. | $34.23 | 2020 | |
| Galderma Laboratories, L.P. | $32.36 | 2021 | |
| Organon LLC | $27.50 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $25.84 | 2019 | |
| Glaxosmithkline, LLC. | $25.52 | 2019-2021 | |
| Alk-Abello, INC | $25.21 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $24.80 | 2019-2021 | |
| Phadia US INC. | $23.20 | 2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $20.45 | 2025 | |
| Ironshore Pharmaceuticals INC. | $18.31 | 2019 | |
| Aytu Biopharma, INC. | $18.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.52 | 2023 | Flumist Quadrivalent |
| Supernus Pharmaceuticals, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Crow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.